Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tobira Therapeutics

Request full access

A biotechnology company engaging in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious…

Manalapan Township, United StatesFounded 2006Biotech & Life Sciences

About Tobira Therapeutics

Tobira Therapeutics, Inc. operated as a clinical-stage biopharmaceutical company, established in 2006 with a strategic focus on therapies for liver disease, fibrosis, and HIV-1. The company's business model centered on the development and eventual commercialization of pharmaceutical assets, with its lead product candidate being cenicriviroc (CVC). This drug is an orally administered immunomodulator designed as a dual antagonist of the CCR2 and CCR5 chemokine receptors, which are implicated in inflammatory and fibrotic disease pathways.

The company's primary therapeutic target for CVC was non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease with no approved treatments, which can lead to cirrhosis and liver failure. Tobira initiated the CENTAUR Phase 2b clinical trial to assess CVC's efficacy in adults with NASH and liver fibrosis. While the study did not meet its primary endpoint, it demonstrated a statistically significant improvement in fibrosis without the worsening of NASH, a key secondary endpoint that supported further development. This ultimately led to the design of the global AURORA Phase 3 trial. CVC was also positioned as a potential treatment for HIV-1, having completed Phase 2 trials demonstrating its safety profile in infected subjects.

Dr. Laurent Fischer, a seasoned executive with extensive experience in liver disease and virology at companies like Hoffmann-La Roche and DuPont-Merck, led Tobira as its Chief Executive Officer from March 2014. His background includes the successful launch of major HIV therapies, which was highly relevant to Tobira's dual-pipeline strategy. A significant milestone in the company's history occurred in November 2016, when it was acquired by Allergan plc (now part of AbbVie) in a deal valued at up to $1.7 billion. The acquisition integrated CVC and another pipeline asset, evogliptin, into Allergan's gastroenterology research and development portfolio, aiming to create a leading position in the burgeoning NASH market.

Source: Dealroom company data

Tobira Therapeutics in the Manalapan Township ecosystem

Live from Dealroom

The Tobira Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Frazier Healthcare Partners
  • Canaan
  • Montreux Equity Partners
  • Domain Associates

Series B and later2 investors entered at this stage

  • RMI Partners
  • Oxford Finance
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Manalapan Township HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tobira Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tobira Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.